Delcath Systems, Inc. focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver.
Market Cap | 42.774 Million | Shares Outstanding | 15.276 Million | Avg 30-day Volume | 474.078 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -1.14 |
Price to Revenue | 33.4314 | Debt to Equity | 0.4028 | EBITDA | -33.731 Million |
Price to Book Value | 2.9267 | Operating Margin | -1604.9907999999998 | Enterprise Value | 41.789 Million |
Current Ratio | 3.299 | EPS Growth | 0.086 | Quick Ratio | 2.91 |
1 Yr BETA | 0.0129 | 52-week High/Low | 7.99 / 2.25 | Profit Margin | -2080.1294 |
Operating Cash Flow Growth | -28.84 | Free Cash Flow to Firm (FCFF) TTM | -21.495 Million | Free Cash Flow to Equity (FCFE) TTM | -17.324 Million |
Altman Z-Score | -14.1916 |
Please sign in first
244.5 Thousand total shares from 5 transactions
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
1,038,828 | 2023-11-17 | 5 | |
PENNELL SANDRA SVP OF FINANCE, PFO AND PAO |
|
30,000 | 2023-11-17 | 3 |
VUKOVIC VOJO CHIEF MEDICAL OFFICER |
|
60,000 | 2023-11-16 | 2 |
HOFFMAN DAVID L. SEE REMARKS |
|
40,000 | 2023-11-16 | 2 |
PURPURA JOHN CHIEF OPERATING OFFICER |
|
41,526 | 2023-10-13 | 2 |
|
10,550 | 2023-08-21 | 2 | |
MICHEL GERARD J CHIEF EXECUTIVE OFFICER |
|
228,345 | 2023-08-18 | 4 |
|
0 | 2023-06-12 | 1 | |
|
0 | 2023-06-12 | 1 | |
|
0 | 2023-06-12 | 3 | |
|
0 | 2023-06-12 | 2 | |
JOHN JOHNNY SEE REMARKS |
|
0 | 2023-06-12 | 1 |
MUIR KEVIN SEE REMARKS |
|
0 | 2023-06-12 | 1 |
|
459,315 | 2022-12-14 | 5 | |
DIAS ANTHONY VICE PRESIDENT OF FINANCE |
|
0 | 2022-05-04 | 0 |
PADULA CHRISTINE SEE REMARKS |
|
30,000 | 2021-09-01 | 0 |
|
6,014 | 2020-05-08 | 0 | |
|
6,001 | 2020-05-08 | 0 | |
KECK BARBRA SEE REMARKS |
|
12,851 | 2020-05-06 | 0 |
SIMPSON JENNIFER K. PRESIDENT AND CEO |
|
25,021 | 2020-05-06 | 0 |
|
0 | 2019-02-01 | 0 | |
|
205,299 | 2015-07-22 | 0 | |
|
20,000 | 2015-06-10 | 0 | |
|
45,052 | 2015-06-10 | 0 | |
|
7,938 | 2014-07-10 | 0 | |
|
21,485 | 2014-07-07 | 0 | |
|
11,678 | 2014-07-07 | 0 | |
|
11,678 | 2014-07-07 | 0 | |
GRAHAM PETER J EVP; GENERAL COUNSEL |
|
0 | 2013-11-14 | 0 |
MIAO GRAHAM G INTERIM CO-CEO & PRES.EVP, CFO |
|
0 | 2013-11-14 | 0 |
APPLING WILLIAM M EVP, R&D AND GLOBAL OPERATIONS |
|
0 | 2013-07-15 | 0 |
GAGO AGUSTIN V EVP GLOBAL SALES & MARKETING |
|
0 | 2013-03-11 | 0 |
HOBBS EAMONN P PRESIDENT AND CEO |
|
0 | 2013-03-11 | 0 |
MAPES HAROLD EXEC. V. P., GLOBAL OPERATIONS |
|
0 | 2013-03-11 | 0 |
KANDARPA KRISHNA EXEC. V.P., CHIEF MEDICAL OFF. |
|
0 | 2013-03-11 | 0 |
|
700,828 | 2012-06-15 | 0 | |
MCDONALD DAVID CHIEF FINANCIAL OFFICER |
|
47,706 | 2011-03-10 | 0 |
|
8,507 | 2010-12-01 | 0 | |
|
211,485 | 2009-12-10 | 0 | |
RIFKIN JASON ANDREW SR. VP CLINICAL OPER. & SECY |
|
0 | 2009-10-12 | 0 |
|
10,000 | 2008-06-30 | 0 | |
FEINSTEIN PAUL M CHIEF FINANCIAL OFFICER |
|
35,000 | 2007-11-30 | 0 |
HERSCHKOWITZ SAMUEL /FA/ CHIEF OPERATING OFFICER |
|
160,375 | 2007-05-25 | 0 |
ISDANER DANIEL |
|
478,893 | 2007-04-16 | 0 |
|
660,626 | 2007-04-16 | 0 | |
|
1,450,710 | 2007-01-26 | 0 | |
NEVINS VICTOR |
|
180,007 | 2006-10-12 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-11-21 07:42:49 -0500 | 2023-11-17 | P | 30,000 | $2.43 | a | 30,000 | direct | -2.3649 | -5.4054 | 1.0135 | 3 | -5.4054 | 6 | |||
ROSALIND ADVISORS, INC. - Director by rosalind advisors, inc., the advisor to the rosalind funds SALAMON STEVEN A J - Director by rosalind advisors, inc., the advisor to the rosalind funds AHARON GIL - Director by rosalind advisors, inc., the advisor to the rosalind funds |
2023-11-21 11:07:33 -0500 | 2023-11-17 | P | 100,000 | $2.40 | a | 1,038,828 | indirect | -2.3649 | -5.4054 | 1.0135 | 3 | -5.4054 | 6 | ||
2023-11-20 16:20:28 -0500 | 2023-11-16 | P | 40,000 | $2.48 | a | 40,000 | direct | -2.3649 | -5.4054 | 1.0135 | 3 | -5.4054 | 6 | |||
2023-11-20 16:22:23 -0500 | 2023-11-16 | P | 60,000 | $2.48 | a | 60,000 | direct | -2.3649 | -5.4054 | 1.0135 | 3 | -5.4054 | 6 | |||
2023-10-17 16:53:31 -0400 | 2023-10-13 | P | 14,505 | $3.44 | a | 41,526 | direct | -2.3684 | -9.4737 | 0.0 | 1 | -9.4737 | 6 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
DELCATH SYSTEMS INC DCTH | 2023-11-30 20:16:16 UTC | 0.911 | 4.409 | 950000 |
DELCATH SYSTEMS INC DCTH | 2023-11-30 19:45:03 UTC | 0.911 | 4.409 | 950000 |
DELCATH SYSTEMS INC DCTH | 2023-11-30 19:15:04 UTC | 0.911 | 4.409 | 950000 |
DELCATH SYSTEMS INC DCTH | 2023-11-30 18:45:04 UTC | 0.911 | 4.409 | 950000 |
DELCATH SYSTEMS INC DCTH | 2023-11-30 18:15:04 UTC | 0.911 | 4.409 | 950000 |
DELCATH SYSTEMS INC DCTH | 2023-11-30 17:45:04 UTC | 0.911 | 4.409 | 950000 |
DELCATH SYSTEMS INC DCTH | 2023-11-30 17:15:04 UTC | 0.911 | 4.409 | 950000 |
DELCATH SYSTEMS INC DCTH | 2023-11-30 16:45:03 UTC | 0.903 | 4.417 | 950000 |
DELCATH SYSTEMS INC DCTH | 2023-11-30 16:15:04 UTC | 0.903 | 4.417 | 950000 |
DELCATH SYSTEMS INC DCTH | 2023-11-30 15:45:04 UTC | 0.903 | 4.417 | 950000 |
DELCATH SYSTEMS INC DCTH | 2023-11-30 15:15:04 UTC | 0.903 | 4.417 | 950000 |
DELCATH SYSTEMS INC DCTH | 2023-11-30 14:45:04 UTC | 0.903 | 4.417 | 950000 |
DELCATH SYSTEMS INC DCTH | 2023-11-30 14:15:04 UTC | 0.903 | 4.417 | 950000 |
DELCATH SYSTEMS INC DCTH | 2023-11-30 13:45:04 UTC | 0.8892 | 4.4308 | 950000 |
DELCATH SYSTEMS INC DCTH | 2023-11-30 13:15:04 UTC | 0.8892 | 4.4308 | 950000 |
DELCATH SYSTEMS INC DCTH | 2023-11-30 12:45:03 UTC | 0.8892 | 4.4308 | 900000 |
DELCATH SYSTEMS INC DCTH | 2023-11-29 22:15:05 UTC | 0.8892 | 4.4308 | 1000000 |
DELCATH SYSTEMS INC DCTH | 2023-11-29 21:45:04 UTC | 0.8892 | 4.4308 | 1000000 |
DELCATH SYSTEMS INC DCTH | 2023-11-29 21:15:05 UTC | 0.8892 | 4.4308 | 1000000 |
DELCATH SYSTEMS INC DCTH | 2023-11-29 20:45:04 UTC | 0.8892 | 4.4308 | 1000000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|